NIH presents supporting data on Theralux™-ATIR during ASH
During the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH), Dr. Stephan Mielke (NIH), has presented supporting results on Theralux™-ATIR. The data demonstrated that host-reactive T cells can be selectively eliminated from donor stem cell allografts under clinical scale conditions. The manipulated T cell allograft left behind a broad repertoire of T cells which can provide immunity against infection and prevent disease relapse.
NIH announced to conduct a Clinical Trial using Kiadis Pharma’s Theralux™-ATIR technology.
To read more, click here for the complete press release.
More news
- Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia - Partnership would advance innovative stem cell transplant product 4-1-2011
- Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 8-7-2010
- Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-4-2010
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™ 29-11-2009
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting 5-11-2009
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium 8-4-2009
- Kiadis Pharma presents at the EBMT in Göteborg 31-3-2009
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting 6-2-2009
- Kiadis Pharma appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer 6-1-2009
- Kiadis Pharma announces appointment of Mark Skaletsky to its Supervisory Board 11-12-2008
